The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation

Clinical trial NCT04217135 · UNKNOWN

Trial details

NCT number: NCT04217135
Sponsor: Kaohsiung Veterans General Hospital.
Status: UNKNOWN
Phase: Phase 4
Study type: INTERVENTIONAL

Systolic Heart Failure Stage D (Disorder)Mitral Regurgitation

Start date: 2017-01-01
Primary completion: 2022-07-31
Enrollment: 400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.